Complement and Podocytopathies: Do We Have a New Biomarker?
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Eddy A, Symons J
. Nephrotic syndrome in childhood. Lancet. 2003; 362(9384):629-39.
DOI: 10.1016/S0140-6736(03)14184-0.
View
2.
Han R, Hu S, Qin W, Shi J, Hou Q, Wang X
. C3a and suPAR drive versican V1 expression in tubular cells of focal segmental glomerulosclerosis. JCI Insight. 2019; 4(13).
PMC: 6629242.
DOI: 10.1172/jci.insight.130986.
View
3.
Ahn W, Bomback A
. Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020. Am J Kidney Dis. 2020; 75(6):955-964.
DOI: 10.1053/j.ajkd.2019.12.019.
View
4.
Trachtman H, Laskowski J, Lee C, Renner B, Feemster A, Parikh S
. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Renal Physiol. 2021; 321(4):F505-F516.
PMC: 8560405.
DOI: 10.1152/ajprenal.00041.2021.
View
5.
Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S
. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol. 2000; 11(4):700-707.
DOI: 10.1681/ASN.V114700.
View